Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
about
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpuraThe role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpuraA randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab.An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura.Evaluation and management of patients with thrombotic thrombocytopenic purpura.Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange.The potential utility of B cell-directed biologic therapy in autoimmune diseases.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection.The kidney in thrombotic thrombocytopenic purpura.Rituximab in the treatment of autoimmune haematological disorders.Thrombotic thrombocytopenic purpura is associated with a high relapse rate after plasma exchange: a single-centre experience.Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experienceRituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome[Thrombotic-thrombocytopenic purpura].ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcomeInvestigational drugs in thrombotic thrombocytopenic purpura.Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.Long-term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements.A case series of atypical presentations of thrombotic thrombocytopenic purpura.Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura.Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in a patient with metastatic neuroendocrine tumour successfully treated with rituximab-CVP.Thrombotic microangiopathy and associated renal disorders.Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports.Goodpasture's syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit.Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature.Management and outcomes for patients with TTP: analysis of 100 cases at a single institution.Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.High frequency of acquired ADAMTS13 deficiency after hemolysis in Hemiscorpius Lepturus (scorpion) stung children.
P2860
Q24241470-BD61C142-8226-43F4-AFAC-0AF2C12AC195Q28080631-2F36FF1F-9508-4880-B100-38BC77985A4AQ30441694-D46E98D4-CB93-4421-8F72-CEBD02597A55Q33327295-77AC9857-85DF-4848-911F-D3D6CBBA25A2Q33369692-D1557506-FA57-4EE0-854B-ED1F033B6E81Q33369765-79F85530-F5ED-4881-8B7B-56B2A5A1883DQ33372991-75F9E826-ECB7-4B69-AF17-DD761F60B169Q33373112-18C22042-A8EB-4CA2-925E-E9E3ED8FB9FCQ33373912-1EDC8F32-7BD6-42FF-9AB0-557EE56C6CE5Q33374294-DA98BAE0-0B50-4D17-A7E9-AC245436AAC3Q33374400-A67A23C0-E355-466B-B5FD-16AAD4F124AFQ33375004-364ADB2D-F2F1-4BA1-9243-CB42C3562F07Q33375264-B254242F-C39B-40DD-B4D5-F9544DAA1D4DQ33377109-FED67EB8-0199-4DB4-93DC-741DAF6B03ADQ33377727-87436A72-DC66-4E63-8D34-51CFBE89F2FEQ33378414-EADE12F7-C755-412D-BD63-A7EACE7DD1D9Q33378755-49C2680A-9093-4442-B91A-5CC099A8E7DEQ33378854-26A2905D-045B-4BBB-BFAA-9818E55F5D30Q33379313-D94B00EA-B64C-417B-8DA7-3DB11A587381Q33389392-B8F2A7FE-AA4C-4CB7-A02B-AD9F48008F77Q33389561-74C6D5D9-4413-444A-B700-EDEE78F973ADQ33391086-7582A435-FFDC-4FC8-A4F9-8B9C7B908064Q33391233-7CA3AF74-06E5-4AD2-AD53-4CD44F61B937Q33395460-404A635E-5230-4D81-A4B6-50D8898D84C9Q33395696-306E790B-0487-4825-9B8D-B8146E6B2FC6Q33397081-1DCDA970-8410-4115-A397-78AB70A882B4Q33399639-92E366ED-2013-4FC2-801C-206B8FB57F6BQ33400508-4C488603-6DD6-485D-AA02-35586602A22CQ33400631-E7BE5BB9-C19E-4B29-A154-C5BF1B5DA434Q33401010-DE8D5BAF-4169-415B-A009-761E28AB54A1Q33401049-FB7D11A9-3E39-4C75-996A-0242AB774666Q33401403-7FBCE0F2-E054-4E04-8EAB-BF2229DC3140Q33402349-43A5E156-2897-415E-A8E5-0212BBB1C3A1Q33402372-23625310-8011-40E6-9AAC-0B13619A2C3FQ33402749-47444220-DAD6-417C-B9CB-0479F51FF0BEQ33404118-10EE5C54-D76B-4B7F-8FCE-094F4A875DE3Q33404199-4200D96D-9F44-4640-81BA-B7494837E086Q33407187-2352BC63-8603-49D3-A5B5-8B842A489DE5Q33409112-67150D33-3865-4701-963C-5F36133654CEQ33409389-A286F04C-D64B-4B6A-85AA-5DF146635F38
P2860
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Efficiency of curative and pro ...... purpura: a study of 11 cases.
@ast
Efficiency of curative and pro ...... purpura: a study of 11 cases.
@en
type
label
Efficiency of curative and pro ...... purpura: a study of 11 cases.
@ast
Efficiency of curative and pro ...... purpura: a study of 11 cases.
@en
prefLabel
Efficiency of curative and pro ...... purpura: a study of 11 cases.
@ast
Efficiency of curative and pro ...... purpura: a study of 11 cases.
@en
P2093
P50
P1433
P1476
Efficiency of curative and pro ...... purpura: a study of 11 cases.
@en
P2093
Agnès Veyradier
Benjamin Deroure
Fadi Fakhouri
Friedrich Scheiflinger
Gilles Kaplanski
Jean-Paul Vernant
Jean-Pierre Grünfeld
Manfred Rieger
Martine Wolf
Pascale Poullin
P304
P356
10.1182/BLOOD-2005-03-0848
P407
P577
2005-06-02T00:00:00Z